Zacks Investment Research cut shares of Genmab A/S (OTCMKTS:GNMSF) from a buy rating to a hold rating in a report released on Tuesday morning.

According to Zacks, “Genmab A/S is a biotechnology company that creates and develops human antibodies for the treatment of life-threatening and debilitating diseases. Genmab has numerous products in development to treat cancer, infectious disease, rheumatoid arthritis and other inflammatory conditions, and intends to continue assembling a broad portfolio of new therapeutic products. In addition, Genmab has developed UniBody, a new proprietary technology that creates a stable, smaller antibody format. Genmab has operations in Europe and the US. “

Separately, JPMorgan Chase & Co. initiated coverage on shares of Genmab A/S in a research note on Tuesday, June 21st. They set a neutral rating on the stock.

Shares of Genmab A/S (OTCMKTS:GNMSF) opened at 158.25 on Tuesday. Genmab A/S has a 52 week low of $93.25 and a 52 week high of $183.00. The firm’s 50-day moving average is $162.19 and its 200 day moving average is $161.78. The firm has a market capitalization of $9.47 billion, a PE ratio of 94.70 and a beta of 0.75.

Receive News & Stock Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related stocks with our FREE daily email newsletter.